Literature DB >> 19149554

Pirate primates in uncharted waters: lymphocyte transfers in unrelated, MHC-matched macaques.

Benjamin J Burwitz1, Justin M Greene, David H O'Connor.   

Abstract

An HIV vaccine remains elusive despite the concerted efforts of investigators and clinicians over the past two decades. Animal models are regularly used to obtain new insights on disease pathogenesis and have become invaluable tools in the translation of treatments from basic research laboratories to the clinic. Vaccination of macaques with live, attenuated simian immunodeficiency virus is currently the most effective method of garnering protection against subsequent pathogenic SIV challenge. However, immunization of humans with live, attenuated HIV is not feasible due to safety concerns. Therefore, clues to an effective and safe vaccine against HIV may be found by studying immune correlates of protection in the live, attenuated, vaccinated macaque model. Previous studies have identified the immune correlates of protection against Friend retrovirus in live, attenuated vaccinated mice using allogeneic adoptive transfers. Similar experiments in macaques have thus far been hindered due to the vast genetic diversity found within outbred populations. Here we review the current state of SIV adoptive transfer research and present a novel macaque model that allows for allogeneic adoptive transfers.

Entities:  

Mesh:

Year:  2009        PMID: 19149554      PMCID: PMC4509675          DOI: 10.2174/157016209787048492

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  53 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys.

Authors:  F Titti; L Sernicola; A Geraci; G Panzini; S Di Fabio; R Belli; F Monardo; A Borsetti; M T Maggiorella; M Koanga-Mogtomo; F Corrias; R Zamarchi; A Amadori; L Chieco-Bianchi; P Verani
Journal:  J Gen Virol       Date:  1997-10       Impact factor: 3.891

3.  Retracing our STEP towards a successful CTL-based HIV-1 vaccine.

Authors:  Otto O Yang
Journal:  Vaccine       Date:  2008-02-27       Impact factor: 3.641

4.  Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus.

Authors:  S Norley; B Beer; D Binninger-Schinzel; C Cosma; R Kurth
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

5.  Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

Authors:  Bruce L Levine; Wendy B Bernstein; Naomi E Aronson; Katia Schlienger; Julio Cotte; Steven Perfetto; Mary J Humphries; Silvia Ratto-Kim; Deborah L Birx; Carolyn Steffens; Alan Landay; Richard G Carroll; Carl H June
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

6.  A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins.

Authors:  R Walker; R M Blaese; C S Carter; L Chang; H Klein; H C Lane; S F Leitman; C A Mullen; M Larson
Journal:  Hum Gene Ther       Date:  1993-10       Impact factor: 5.695

7.  Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques.

Authors:  A Gallimore; M Cranage; N Cook; N Almond; J Bootman; E Rud; P Silvera; M Dennis; T Corcoran; J Stott
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

8.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

9.  The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Authors:  Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

10.  Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaques.

Authors:  Justin M Greene; Benjamin J Burwitz; Alex J Blasky; Teresa L Mattila; Jung Joo Hong; Eva G Rakasz; Roger W Wiseman; Kim J Hasenkrug; Pamela J Skinner; Shelby L O'Connor; David H O'Connor
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

View more
  2 in total

1.  Adoptive transfer of lymphocytes isolated from simian immunodeficiency virus SIVmac239Δnef-vaccinated macaques does not affect acute-phase viral loads but may reduce chronic-phase viral loads in major histocompatibility complex-matched recipients.

Authors:  Justin M Greene; Jennifer J Lhost; Paul J Hines; Matthew Scarlotta; Max Harris; Benjamin J Burwitz; Melisa L Budde; Dawn M Dudley; Ngoc Pham; Brian Cain; Caitlin E Mac Nair; Madelyn K Weiker; Shelby L O'Connor; Thomas C Friedrich; David H O'Connor
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

2.  Rapid, repeated, low-dose challenges with SIVmac239 infect animals in a condensed challenge window.

Authors:  Justin M Greene; Andrea M Weiler; Matthew R Reynolds; Brian T Cain; Ngoc H Pham; Adam J Ericsen; Eric J Peterson; Kristin Crosno; Kevin Brunner; Thomas C Friedrich; David H O'Connor
Journal:  Retrovirology       Date:  2014-08-14       Impact factor: 4.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.